Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (610)	2/1/2002 9:57:42 AM
From: tuck	Read Replies (1) \| Respond to of 1005

Yet another victim for BLUE H: >>SEATTLE, Feb. 1 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. announced today an initial public offering of 10,000,000 shares of its common stock at $12.00 per share. All of the shares offered are being sold by ZymoGenetics. The joint book-running managers for the offering are Lehman Brothers Inc. and Merrill Lynch & Co. Bear, Stearns & Co. Inc. and Pacific Growth Equities, Inc. are the co-managers. ZymoGenetics has granted the underwriters of the offering an option to purchase up to an additional 1,500,000 shares of its common stock to cover over-allotments, if any. ZymoGenetics' shares will be quoted on the Nasdaq National Market under the trading symbol ``ZGEN.'' ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic protein-based products for the prevention or treatment of human diseases. Copies of the final prospectus relating to the offering may be obtained from Lehman Brothers Inc., c/o ADP Financial Services, Prospectus Fulfillment, 55 Mercedes Way, Edgewood, NY 11717, (631) 254-7105; Merrill Lynch & Co, 4 World Financial Center, 5th Floor, New York, NY 10080; Bear, Stearns & Co. Inc., 383 Madison Avenue, New York, NY 10179, (631) 254-7129; or Pacific Growth Equities, Inc., Four Maritime Plaza, San Francisco, CA 94111, (415) 274-6800. Contact: Charles E. Hart, Ph.D. Senior Director of Corporate Communication and Investor Relations ZymoGenetics, Inc. (206) 442-6744 www.zymogenetics.com<< Here's the link to the S-1 sec.gov Cheers, Tuck